TY - JOUR
T1 - Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible?
T2 - A randomized multicenter pilot trial
AU - Nguyen, K P
AU - Knuiman, G J
AU - Blokx, W A M
AU - Hoogedoorn, L
AU - Smits, T
AU - Gerritsen, M J P
N1 - Funding Information:
This work was funded by Galderma S.A., Switzerland.
Funding Information:
Nguyen and Hoogedoorn received financial support from Galderma for performing clinical trials.
Publisher Copyright:
© 2018, © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/3
Y1 - 2019/3
N2 - BACKGROUND: Topical methyl aminolevulinate photodynamic therapy (MAL-PDT) is highly effective for the treatment of superficial basal cell carcinoma (sBCC). Current European treatment protocol requires two hospital visits, which is costly and unpractical. The aim of this study was to evaluate the efficacy of fractionated MAL-PDT, using two light fractions at 3 and 4 h compared to illumination at 3 and 5 h after MAL-application.METHODS: Thirty patients were randomized into two groups. The first group received illumination at 3 and 4 h (20 + 55 J/cm2) after MAL-application (3/4 group). In the other group, two light fractions were performed at 3 and 5 h (20 + 55 J/cm2) after MAL-application (3/5 group). The lesion response was evaluated at 3 and 12 months posttreatment.RESULTS: In the 3/5 group, 70.0% showed a complete response (CR) at 3 months compared to 63.6% in the other group. At 12 months, 100% showed a CR in the 3/5 group compared to 80.0% in the other group. However, most failures/recurrences were eventually due to the presence of a more aggressive BCC subtype, mostly caused by sampling error of the primary punch biopsy.CONCLUSION: Single day protocol for MAL-PDT for sBCC is feasible and this study shows promising results.
AB - BACKGROUND: Topical methyl aminolevulinate photodynamic therapy (MAL-PDT) is highly effective for the treatment of superficial basal cell carcinoma (sBCC). Current European treatment protocol requires two hospital visits, which is costly and unpractical. The aim of this study was to evaluate the efficacy of fractionated MAL-PDT, using two light fractions at 3 and 4 h compared to illumination at 3 and 5 h after MAL-application.METHODS: Thirty patients were randomized into two groups. The first group received illumination at 3 and 4 h (20 + 55 J/cm2) after MAL-application (3/4 group). In the other group, two light fractions were performed at 3 and 5 h (20 + 55 J/cm2) after MAL-application (3/5 group). The lesion response was evaluated at 3 and 12 months posttreatment.RESULTS: In the 3/5 group, 70.0% showed a complete response (CR) at 3 months compared to 63.6% in the other group. At 12 months, 100% showed a CR in the 3/5 group compared to 80.0% in the other group. However, most failures/recurrences were eventually due to the presence of a more aggressive BCC subtype, mostly caused by sampling error of the primary punch biopsy.CONCLUSION: Single day protocol for MAL-PDT for sBCC is feasible and this study shows promising results.
KW - Superficial basal cell carcinoma
KW - fractionated illumination
KW - methyl aminolevulinate
KW - photodynamic therapy
KW - Photosensitizing Agents/therapeutic use
KW - Humans
KW - Middle Aged
KW - Neoplasm Recurrence, Local
KW - Male
KW - Photochemotherapy/methods
KW - Pilot Projects
KW - Adult
KW - Female
KW - Aged
KW - Carcinoma, Basal Cell/drug therapy
KW - Aminolevulinic Acid/analogs & derivatives
UR - http://www.scopus.com/inward/record.url?scp=85051969921&partnerID=8YFLogxK
U2 - 10.1080/09546634.2018.1484558
DO - 10.1080/09546634.2018.1484558
M3 - Article
C2 - 29862877
SN - 0954-6634
VL - 30
SP - 194
EP - 199
JO - The journal of dermatological treatment
JF - The journal of dermatological treatment
IS - 2
ER -